Michael Morrissey

In the last six months, Exelixis, Inc. (NASDAQ: EXEL) soared more than 200% on the news that the company is developing a promising drug to combat prostate cancer. Michael Morrissey, CEO of Exelixis, told CNBC that the drug tackles both the tumor and the bone complications (prostate cancer “...